What Is Zotatifin? Mechanism, Uses, and Side Effects

Zotatifin is an investigational small molecule drug currently undergoing study in clinical trials. It is classified as a selective inhibitor of eukaryotic translation initiation factor 4A (eIF4A), a protein involved in making new proteins. As an investigational agent, zotatifin is not yet approved for widespread public use, and its full therapeutic potential and safety profile are still being evaluated.

Mechanism of Action

Cells continuously produce proteins through a process called protein synthesis. This process begins with the translation of genetic instructions from messenger RNA (mRNA) into proteins. Eukaryotic initiation factor 4A (eIF4A) plays a significant role in this initial step.

EIF4A functions as an RNA helicase, unwinding complex folded structures within the 5′-untranslated region (5′-UTR) of mRNA molecules. This unwinding action is necessary to allow the cellular machinery, specifically the 43S ribosome pre-initiation complex, to scan along the mRNA and begin protein production. Zotatifin intervenes by binding to eIF4A, promoting its stable association with specific polypurine motifs within these mRNA 5′-UTRs.

This drug-induced binding forms a stable complex involving eIF4A, zotatifin, and the mRNA. This “clamping” action prevents eIF4A from unwinding mRNA structures, blocking the ribosome’s ability to scan and initiate translation. By disrupting this step, zotatifin represses the production of proteins that rapidly dividing cells, such as cancer cells, rely on for growth and survival.

Proteins whose synthesis is repressed by zotatifin include oncogenes like MYC, KRAS, myeloid cell leukemia-1 (MCL-1), and B-cell lymphoma 2 (BCL-2). It also represses cell cycle regulators such as cyclin-dependent kinase (CDK) 4 and 6, and cyclin D. These proteins are often overexpressed in cancer, driving tumor proliferation and metastasis.

Applications in Cancer Treatment

Zotatifin is being investigated for its potential in treating various cancers that depend on the protein synthesis pathways it targets. A prominent area of focus is estrogen receptor-positive (ER+) breast cancer, where zotatifin is being evaluated in combination with other therapies.

In ER+ breast cancer, zotatifin is studied with fulvestrant and abemaciclib, forming the ZFA triplet. This combination has shown preliminary anti-tumor activity in heavily pretreated patients, with partial responses observed in early-phase trials. Its use in these cancers is based on its ability to downregulate proteins like ERα and CDK4/6, which are implicated in ER+ breast cancer growth.

Beyond breast cancer, zotatifin has been explored in other malignancies. Preclinical studies show its potential in castration-resistant prostate cancer (CRPC), where it inhibited tumor growth and even caused tumor shrinkage in patient-derived xenograft models. This effect is linked to its ability to reduce the synthesis of oncogenes like the androgen receptor and hypoxia-inducible factor 1A (HIF1A), which drive CRPC.

Zotatifin is also under investigation for KRAS-mutant non-small cell lung cancer (NSCLC) and has shown promise in preclinical models of triple-negative breast cancer (TNBC). While an earlier monotherapy trial in CRPC showed limited standalone activity, development has shifted towards its use in combination with other agents to enhance therapeutic effect.

Use in Viral Infections

Beyond its cancer applications, zotatifin has also been explored as a potential antiviral agent. Viruses, including coronaviruses like SARS-CoV-2, hijack the host cell’s protein synthesis pathways to produce proteins necessary for their replication.

Since zotatifin inhibits the host cell’s protein synthesis, it can interfere with the viral life cycle. Research has demonstrated zotatifin’s effectiveness against SARS-CoV-2, the virus responsible for COVID-19. It reduces viral infectivity by inhibiting the biogenesis of SARS-CoV-2 nucleoprotein (NP).

Zotatifin can clamp the 5′-untranslated regions (5′-UTRs) of viral messenger RNAs onto the eIF4A helicase. This action blocks the initiation of viral protein translation. In cell-based models, zotatifin has been observed to decrease the detection of viral NP protein and reduce viral infectivity in a concentration-dependent manner.

This host-directed approach to antiviral therapy targets a cellular process rather than specific viral components, which may reduce the likelihood of viral resistance. Zotatifin’s ability to disrupt the host cell’s protein production machinery offers a broad-spectrum strategy against various RNA viruses that rely on similar mechanisms.

Clinical Trial Status and Side Effects

Zotatifin is currently in early-phase clinical trials, primarily Phase 1/2 studies. These trials assess the drug’s safety, determine appropriate dosages, and provide initial insights into its effectiveness. The main clinical trial for zotatifin in solid tumors is registered as NCT04092673.

In trials for ER+ breast cancer, where zotatifin is tested in combination with fulvestrant and abemaciclib (the ZFA triplet), the drug has generally been well tolerated. The most commonly reported side effects were mild to moderate (Grade 1 or 2). These included diarrhea, nausea, vomiting, and fatigue.

More specifically, in a triplet cohort, common side effects included diarrhea, nausea, and vomiting. Other reported side effects, though less frequent, included abdominal pain and anemia. More severe (Grade 3 or higher) adverse events were less common.

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the zotatifin triplet in ER+/HER2- advanced or metastatic breast cancer, recognizing its potential to address unmet medical needs. Zotatifin remains an investigational drug, and its complete safety and effectiveness profile will continue to be evaluated through ongoing trials.

What Is Dynamic Causal Modeling and Why Is It Used?

What Is a Colony Forming Assay? Types & Applications

Zfns and Their Role in Genome Editing Tools